semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Fibromyalgia In order to qualify the subject: 1. must have been diagnosed with fibromyalgia by a medical doctor 2. must be between the ages of 18 to 65 years of age 3. must have a weekly overall body pain average score ≥ 4 4. must pass a screening questionnaire that calculates a physical impairment of ≥ 10 5. must be on stable doses of his/her current medication for at least past four weeks 6. must limit any changes in his/her medication(s) (e.g., dose change, addition or discontinuation of any medication that effects the central nervous system, e.g., benzodiazepines, sedative/hypnotic, etc. ) during the 10-week study period unless medically necessary 7. must report all medication including herbal supplements and over-the-counter medications, e.g. cold medication, eye drops, etc. that he/she is currently taking to a member of the research team 8. must be willing to maintain a medication diary provided to him/her during the 10-week study period 9. must be willing to abstain (not take) any fibromyalgia related medication including over-the-counter for at least 8-hours prior to each of the two testing visits (Otherwise, he/she may take these medication(s) immediately after pain sensitivity testing has been completed and as prescribed in-between visits) 10. must agree to use a proven method of contraception to prevent pregnancy throughout this study  The subject will not be allowed to participate if: 1. he/she has a history of seizures 2. he/she has atopic dermatitis (also called eczema) or chronic urticaria (hives) 3. he/she has chronic thrombocytopenia (a low blood platelet count) 4. she is currently pregnant, are planning to become pregnant, or is breastfeeding 5. he/she has been diagnosed by a psychiatrist with Schizophrenia or bipolar disorder 6. he/she has been diagnosed with another major rheumatic conditions (i.e. rheumatoid arthritis, systemic lupus erythematosus, scleroderma and/or other connective tissue diseases) 7. he/she plans to undergo an elective surgery within the study timeline 8. he/she is in the process of filing, or plan to file for disability benefits within the study timeline 9. his/her screening labs results are abnormal (i.e., elevated SGPT and low platelet count) 10. he/she is currently using any anti-allergy drugs (ophthalmic or oral histamine antagonist), leukotriene inhibitors (e.g., montelukast) or prednisone
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypopituitarism All patients with pituitary hypopituitarism  Unavailability of data
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 1.0-29.0,  Adult Rhabdomyosarcoma Lung Metastases Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Previously Treated Childhood Rhabdomyosarcoma Recurrent Adult Soft Tissue Sarcoma Recurrent Childhood Rhabdomyosarcoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Wilms Tumor and Other Childhood Kidney Tumors Stage IV Adult Soft Tissue Sarcoma Stage IV Wilms Tumor Stage V Wilms Tumor Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific Patients may have a Wilms tumor, Ewing Sarcoma, Rhabdomyosarcoma or any other metastatic pediatric malignancy; patients may have a single or multiple pulmonary metastases at the time of diagnosis or at the time of recurrence; a pulmonary metastasis may be defined as one pulmonary nodule >= 1 cm or more than one pulmonary nodules >= 0.5 cm; a biopsy of the nodules may be considered in case of doubt The Karnofsky performance status must be >= 50 for patients > 16 years of age and the Lansky performance status must be >= 50 for patients =< 16 years of age Patients must not have received prior radiation therapy to any part of the thorax Adequate cardiac function defined as Shortening fraction of >= 27% by echocardiogram, or Ejection fraction of >= 50% by radionuclide angiogram Female patients of childbearing age must have a negative pregnancy test Female patients who are lactating must agree to stop breast-feeding Sexually active patients of childbearing potential must agree to use effective contraception  Patients enrolled on Children's Oncology Group protocols cannot be treated with whole lung IMRT on this study Patients who have a prior history of radiation therapy to the thorax or adjacent regions cannot be entered on this protocol Patient with Hodgkin's Lymphoma are not eligible for this study Patients with mediastinal masses or other pulmonary masses requiring additional mediastinal or lung irradiation beyond the whole lung irradiation (WLI) doses stated in this protocol are ineligible for this study Patients who may require concurrent or sequential irradiation to sites beyond the chest such as the neck, flank, abdomen or liver are eligible for this study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-72.0,  Hypothermia Newborn Estimated gestational age 37 weeks and greater Birth weight greater than 2,500gms Delivery in the hospital  Infant admitted to the NICU Birth weight less than 2,500gms Abdominal wall defect or myelomeningocele Major congenital anomalies Blistering skin disorder
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Obesity Healthy females between the ages of 18-40 (inclusive) BMI > 27 kg/m² Regular menstrual cycle (28 ± 4 days with a maximum of 4 days within-subject variation in menstrual cycle duration Weight stable (within ± 3-kg) 2 months prior to study Must use barrier contraception (e.g. male/female condom) for the study's duration Must be willing to follow the prescribed diet/exercise plan for the study's duration  On hormonal contraceptives (IUD are allowed) or any other daily use of medications which can make the subject unsuitable for in the study Any significant health problem (history of cancer, HIV/AIDS, Diabetes, cardiovascular disease, untreated hypothyroidism, etc.) Restrictions against participating in cardiovascular exercise and strength training Any condition, which in the opinion of the investigator makes the subject unsuitable for in the study Women who are pregnant,lactating, or planning to become pregnant during the study period
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 8.0-16.917,  Anorexia Nervosa Interruption of Growth Delayed Puberty Osteopenia With Failure of Acquisition of Bone Mass Medical screening Female and male subjects aged 8-16 years and 11 months, with clinical anorexia nervosa and / or reference to the diagnostic of DSM-IV (1) before or at early puberty (Tanner stage 1 or 2) and with a prolonged Catch-Down for at least 18 months (HV ≤ 2 cm / year), with bone age ≤ 12 years in girls and ≤14 years in boys Anorexia nervosa diagnosed at least 1 year before the study Growth velocity documented for at least 18 months before As with any child with a severe Catch-Down an assessment of GH secretion must be performed before (in the context of care) in the trial, which is not conditioned by the GH peak value : GH value of <20 miu / L will lead to the production of a brain MRI (in the context of care) that have to be normal (normal hypothalamic-pituitary axis and absence of tumor pathology) to allow of the patient Normal glucose tolerance Stable metabolic state with of weight gain of at least 10% of body weight from the time the body mass index was the lowest in relation to the occurrence of the disease and normal blood electrolytes (no hypokalemia)  Subjects whose holders have signed parental consent Subjects whose holders of parental authority are affiliated to a social security scheme CMU (CMU universal medical coverage)  Subjects in the mid-puberty (Tanner stage 3 or 4) or with menarche Subjects with a chromosomal abnormality or other chronic disease associated chronic requiring long-term treatment Impaired glucose tolerance or diabetes Inability of the patient or the medical team to ensure the progress and monitoring under the protocol Participation in another trial Bradycardia ≤ 50 bpm Children whose holders of parental authority are not beneficiaries of social security Contra-indication to
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Acute Coronary Syndrome Patients admitted in the coronary care unit (CCU) of the Department of Clinical and Experimental Medicine at the Federico 2nd University Hospital Patient with indication to angiographic study even if not immediately Patients referred to CCU with the diagnosis of acute myocardial infraction (AMI), type STEMI, or based on pre-admission assessment of troponin I (TpI) and myocardial band creatin kinase (CK-MB Diagnosis of performed according to standard  Patients who could not undergo angiographic study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Karnofsky ≥ 70 2. Provision of informed consent 3. Pathological confirmation of breast cancer and of other metastases. 4. Pathological confirmation of triple negative or Her-2 positive or with more than 4 axillary lymph node metastasis 5. The patients have finished the chemotherapy of Anthracycline and/or Taxane.And it's no more than 28 days from accepting the last chemotherapy. 6. Laboratory PLT ≥ 100*109/L WBC ≥ 4000/mm3 HGB ≥ 10g/dl GOT,GPT,ALP ≤ 2*ULN TBIL,DBIL,CCr ≤ 1.5*ULN  Pregnant or lactation woman 2. Bilateral breast cancer, inflammatory breast cancer or carcinoma in situ 3. Accepted neoadjuvant treatment including chemotherapy, radiotherapy and endocrine therapy 4. History of organ transplantation 5. With mental disease 6. With severe infection or active gastrointestinal ulcers 7. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes 8. Disease-free period of other malignant tumor is less than 5 years(except cured basal cell skin cancer and cervical carcinoma in situ) 9. With heart disease 10. Experimental drug allergy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Gastric Cancer  Any patients age at GC cancer diagnosis was included. Male and female patients were either included. Healthy volunteers were not included. At the time of diagnosis of cancer patients must be a province of Cremona inhabitants (districts of Crema, Cremona or Casalmaggiore). Informed consent signature was required. TUMOR Diagnosis must be performed from 2010 Juanuary, the 1st to 2013 December, 31st .The diagnosis must be of a infiltrating malignant tumor. The diagnosis should be of a primary tumor. Precancerous diagnosis were not considered. Recidivate tumor were not considered. The site of localization of the tumor at diagnosis must be stomach or gastro - esophageal junction as site of tumor onset. HDGC : Gastric cancer is a known manifestation of inherited cancer predisposition syndromes similar to hereditary nonpolyposis colon cancer and Li-Fraumeni syndrome. According to the OMIM database, more than 90 per cent of gastric cancers are sporadic, whereas less than 10 per cent are hereditary (HDGC). Germline E-cadherin inactivating mutations in the CDH1 gene are responsible for the development of GC in approximately 30% of families with the hereditary diffuse gastric cancer syndrome (HDGC). Diagnostic for HDGC are formulated by the International Gastric Cancer Linkage Consortium in 1999 and then they are reviewed in 2010. In order to individuate HDGC case and to included them in a specialist counselling and CDH-1 gene mutation evaluation, by International GC Linkage Consortium 2010 guidelines were followed
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 45.0-70.0,  Metabolic Syndrome X Women 70 years No menstrual cycle for ≥1 year Stable body weight for ≥6 months (no weight gain/loss > 3 kg) Stable exercise habits during the last 6 months, and not participating in any vigorous exercise program Central obesity: waist circumference ≥80 cm Plus any one of the following four factors Raised triglyceride level: ≥1.7 mmol/L Reduced high-density lipoprotein (HDL) cholesterol: <1.29 mmol/L Raised blood pressure: systolic blood pressure ≥135 mmHg or diastolic BP ≥85 mmHg or use of blood pressure lowering medication Raised fasting plasma glucose ≥ 5.6 mmol/L  (Undiagnosed) Diabetes but not impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) as evaluated by an oral glucose tolerance test at screening Active hearth disease, i.e. history of myocardial infarction, stroke or angina pectoris Active or a history of thyroid disease Cancer or other malignancies in the past 5 years Two sided ovariectomy Drug use knowing to interfere with objectives of the study oral corticosteroids, lipid-lowering drugs (statins) anti-conceptive use (such as the pill or IUD) hormone replacement therapy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Lipid Disorders and Lipid Measurement Patients with age and lipid data are included in the master database. are specific to each individual study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-16.0,  Obesity Adolescents 12 to 16 years and with BMI and weight gain according to sex and age is greater than IMCZ-score > 4 DP> 8 kg 2. Obesity "common" non-syndromic. 3. Medical decision of surgical placement of laparoscopic gastric banding. 4. Adolescent and family who understand and accept the need for medical and surgical follow long term. 5. Adolescent and family who fully understood the oral and written information explaining the study and the need for prolonged follow-up. 6. Obtention of oral and written consent of the adolescent and the parents. 7. Parents and adolescents affiliated with the social security system  Intellectual Deficit. 2. psychiatrics contraindication of surgical placement of laparoscopic gastric banding. 3. Obesity with severe binge eating. 4. Pregnancy or wishes of pregnancy in the following year. 5. Non accession adolescent and / or family in the process of medical care before inclusion. 6. Predictable post surgical monitoring difficulties. 7. Suspicion of physical abuse, verbal or negligence / deficiency in care of the family. 8. Participation in a clinical study evaluating a treatment during the 2 years of the study. 9. Anesthetic contre indication for placement of a gastric laparoscopic. 10. IMC> 50 kg/m2 the day of inclusion
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Anorexia Nervosa Female Age above 18 Restrictive anorexia nervosa with a disease duration more than one year and less than three years Body Mass Index below 16 Patient receiving or having received optimal treatment for anorexia nervosa Right-handed Normal blood ionogramme Previous stable antidepressor treatment for one month and no expected modification in the three following months Patients arriving by car with someone else or by public transportation  Pregnancy Contraindication to transcranial magnetic stimulation i.e. pace-maker, cardiac valve protheses, metallic protheses etc History of epileptic seizure Cerebral lesion of any etiology (post-traumatic, tumoral, vascular etc.) History of previous rTMS
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neck Pain Back Pain Patients receiving SI joint or epidural corticosteroid injections At least 18 years of age  Contraindication to corticosteroid injection (infection; pregnancy; uncontrolled diabetes mellitus [per patient's report]; active congestive heart failure; coagulopathy; medical conditions that prohibit holding anticoagulant or antiplatelet therapy, with the exception of aspirin, for at least two weeks prior to injection; and allergy to iodinated contrast dye, corticosteroids, or amide local anesthetics) Known disorder of the hypothalamic-pituitary-adrenal axis Corticosteroid injection within 6 weeks of study enrollment